×
NEWS

FASLAB receives new funding from the Gilead GÉNESE Program to develop an innovative drug delivery system for the treatment of non-Hodgkin’s lymphoma
20 February 2020

Congratulations to Joana Dias for being awarded a Gilead GENESE grant with the LYMPHOTARGET project.

The LYMPHOTARGET project aims to develop an innovative drug delivery system based on immunoliposomes for the treatment of non-Hodgkin’s lymphoma. By designing antibody-conjugated nanoparticles to selectively target tumor cells and deliver potent antitumor drugs, LYMPHOTARGET aims to establish a novel therapy with a more effective and safer profile for clinical application. The project will be conducted at the FASLab by a multidisciplinary team led by Joana Dias Gomes, in close collaboration with the Institute for Drug Research of the Faculty of Pharmacy, ULisboa.